skip to Main Content

The AIM-HI Accelerator Fund is pleased to be presenting the inaugural Women’s Venture Competition, in which all selected semi-finalists will have the opportunity to benefit from intensive accelerator boot-camp programming by one of the world’s most renowned women entrepreneur accelerator and business training service providers, Springboard Enterprises, and—subject to due diligence and negotiation—the winning business will receive up to $300,000 in AIM-HI investment.

When:

Soon-to-be-Announced Summer 2020 Date

Where:
Online Virtual Pitch Competition

Selection Committee:

Pamela Garzone, Ph.D., Chair

Pamela Garzone, Ph.D., Chair

Chief Medical Officer, Calibr at Scripps Research

Webster Cavenee, Ph.D., Co-chair

Webster Cavenee, Ph.D., Co-chair

Director of Strategic Alliances, Ludwig Institute for Cancer Research

Dimitra Georganopoulou, Ph.D.

Dimitra Georganopoulou, Ph.D.

Innovation Faculty, MIT linQ CATALYST
Interim Chief Business Officer, MyGenome Rx

Marjorie Kaufman, CFA, MBA

Marjorie Kaufman, CFA, MBA

Principal, Osprey Creek LLC

Brian Leyland-Jones, M.B., B.S., Ph.D.

Brian Leyland-Jones, M.B., B.S., Ph.D.

Chief Medical Officer, AIM-HI Accelerator Fund

Patty Obermaier

Patty Obermaier

Vice President, US Health and Life Sciences, Microsoft

Marina Sirota, Ph.D.

Marina Sirota, Ph.D.

Assistant Professor, Institute for Computational Health Sciences, University of California San Francisco

Ashim Subedee, Ph.D.

Ashim Subedee, Ph.D.

Program Director, National Cancer Institute Small Business Innovation Research (SBIR) Development Center

Thea Tlsty, Ph.D.

Thea Tlsty, Ph.D.

Professor of Pathology, University of California San Francisco

Judging Committee:

Barbara Weber, M.D., Chair

Barbara Weber, M.D., Chair

President & CEO, Tango Therapeutics

Raju Kucherlapati, Ph.D., Co-Chair

Raju Kucherlapati, Ph.D., Co-Chair

Paul C. Cabot Professor of Genetics & Professor of Medicine, Harvard Medical School

Joan Brugge, Ph.D.

Joan Brugge, Ph.D.

Louise Foote Pfeiffer Professor of Cell Biology & Director of Ludwig Center, Harvard Medical School

Webster Cavenee, Ph.D.

Webster Cavenee, Ph.D.

Director of Strategic Alliances, Ludwig Institute for Cancer Research

Pamela Garzone, Ph.D.

Pamela Garzone, Ph.D.

Chief Medical Officer, Calibr at Scripps Research

Tom Miller

Tom Miller

Founder & Managing Partner, GreyBird Ventures

Amy Millman

Amy Millman

President & Co-Founder, Springboard Enterprises

Robert Tepper, M.D.

Robert Tepper, M.D.

Partner, Third Rock Ventures

Timeline:

  • Application Deadline: Friday, May 15, 2020, 5:00 PM ET
  • Announcement of Semi-Finalists: On or around Friday, August 7, 2020; E-mail communication to all approved applicants, online to general public
  • Virtual Pitch Competition and Announcement of Finalists: Soon-to-be-determined date in Summer 2020; In person to the selected finalist, online to general public
  • Announcement of Investment: By Fall 2020; In person, e-mail or telephone communication to the selected finalist, online to general public
  • Springboard Enterprises’ Accelerator Bootcamp: Health Innovation Hub—Life Science: To-be-determined dates, likely in the third quarter of 2020; Observer status of highly valuable Boston programming

Eligibility:

  • Application must be submitted by a woman in senior leadership of an oncology start-up company with equity stakes—or planning to set up such a company in the near future. The applicant could be a founder, president, chief executive officer, chief scientific officer or chief medical officer.
  • Applicant must demonstrate track record of milestone achievement, such as, but not necessarily limited to, government or foundation grants, patents, successful clinical trial phases, commercial exits, etc.
  • No fee to apply, but each of the selected finalists must put forward a $250 entrance payment in order to participate in the Women’s Venture Competition.

Format:

A series of private, confidential presentations by the women applicant or individually designated female colleagues. PowerPoint or similar presentation formats are required, and must be delivered—verbally and visually—in English.

Presenters are to be available well in advance of their predesignated time slot, and abide by the to-be-determined time limit (depending on the number of finalists, this will range from a minimum of 30 minutes to a maximum of 45 minutes, including segue and the judging committee feedback and questioning periods), which will be strictly enforced per presentation.

After the conclusion of the event, the two highest rated finalists will be highlighted, and cash awards of $3,000 and $2,000 granted to the winner and runner-up, respectively. Over the following few weeks, the AIM-HI Accelerator Fund will perform detailed due diligence on and communicate with these, the top two Women’s Venture Competition finalists, in order to determine allocation of up to $300,000 in AIM-HI investment into the business deemed to have the stronger potential for return and cancer patient impact.

If you have questions, need more information or are interested in sponsoring this or other AIM-HI Accelerator Fund initiatives, please contact:

Bradley Gillenwater
Senior Director
bgillenwater@aim-hiaccelerator.org

Partner Organizations:

NFCR-logo
Springboard+Logo
AFCR-logo

Sponsor Organizations:

Scripps Research
DSW
BLA

2020 Women’s Venture Competition

Back To Top